The Michigan Vision-Related Anxiety Questionnaire: A Psychosocial Outcomes Measure for Inherited Retinal Degenerations.

Szczegóły
Abstrakt

Tytuł:: The Michigan Vision-Related Anxiety Questionnaire: A Psychosocial Outcomes Measure for Inherited Retinal Degenerations.
Autorzy:: Lacy GD; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abalem MF; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, Brazil.
Andrews CA; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abuzaitoun R; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Popova LT; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Santos EP; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Yu G; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Rakine HY; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Baig N; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Ehrlich JR; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Fahim AT; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Branham KH; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Swenor BK; Johns Hopkins University Wilmer Eye Institute, Baltimore, Maryland, USA.
Lichter PR; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Dagnelie G; Johns Hopkins University Wilmer Eye Institute, Baltimore, Maryland, USA.
Stelmack JA; Illinois Eye and Ear Infirmary, Chicago, Illinois, USA.
Musch DC; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Jayasundera KT; Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA. Electronic address: .
Źródło:: American journal of ophthalmology [Am J Ophthalmol] 2021 May; Vol. 225, pp. 137-146. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Validation Study
Język:: English
Imprint Name(s):: Publication: 1999- : New York, NY : Elsevier Science
Original Publication: [Chicago, etc., Ophthalmic Pub. Co., etc.]
MeSH Terms:: Anxiety Disorders/*diagnosis
Retinal Degeneration/*diagnosis
Vision Disorders/*diagnosis
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anxiety Disorders/psychology ; Female ; Humans ; Male ; Michigan ; Middle Aged ; Patient Reported Outcome Measures ; Psychometrics ; Retinal Degeneration/psychology ; Sickness Impact Profile ; Surveys and Questionnaires ; Vision Disorders/psychology ; Visual Acuity/physiology ; Young Adult
References:: Optom Vis Sci. 2011 Dec;88(12):1496-506. (PMID: 21946786)
Ophthalmic Res. 2015;54(2):78-84. (PMID: 26228470)
Ophthalmic Epidemiol. 2013 Oct;20(5):321-9. (PMID: 24070104)
BMC Ophthalmol. 2018 Jan 30;18(1):21. (PMID: 29378559)
Optom Vis Sci. 2019 Jan;96(1):27-34. (PMID: 30570601)
Qual Life Res. 2007;16 Suppl 1:5-18. (PMID: 17375372)
Transl Vis Sci Technol. 2018 Dec 28;7(6):38. (PMID: 30619658)
Surv Ophthalmol. 2012 Jan-Feb;57(1):34-65. (PMID: 22018676)
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2891-6. (PMID: 20164466)
Eye (Lond). 2012 Jan;26(1):101-8. (PMID: 21997359)
Ophthalmic Genet. 2020 Feb;41(1):1-6. (PMID: 32100594)
Am J Geriatr Psychiatry. 2014 Mar;22(3):309-13. (PMID: 23567435)
Br J Ophthalmol. 2010 Feb;94(2):223-8. (PMID: 20139291)
PLoS One. 2018 Oct 18;13(10):e0206106. (PMID: 30335832)
Optom Vis Sci. 2009 Dec;86(12):1328-36. (PMID: 19844188)
Eur J Ophthalmol. 2015 Sep-Oct;25(5):459-62. (PMID: 25743781)
Ophthalmology. 2015 Apr;122(4):851-61. (PMID: 25573719)
Br J Ophthalmol. 2008 May;92(5):650-4. (PMID: 18356260)
Br J Ophthalmol. 2008 Feb;92(2):252-5. (PMID: 18227205)
Ophthalmic Epidemiol. 2008 Jul-Aug;15(4):218-23. (PMID: 18780254)
Psychosomatics. 2009 Nov-Dec;50(6):613-21. (PMID: 19996233)
Optom Vis Sci. 2013 Aug;90(8):799-805. (PMID: 23851303)
Arch Ophthalmol. 2001 Jul;119(7):1050-8. (PMID: 11448327)
Ophthalmic Genet. 2020 Aug;41(4):315-324. (PMID: 32571121)
Clin Genet. 2013 Aug;84(2):183-9. (PMID: 23662791)
Aust N Z J Ophthalmol. 1998 May;26 Suppl 1:S16-8. (PMID: 9685012)
Retina. 2005 Apr-May;25(3):317-23. (PMID: 15805909)
BMC Ophthalmol. 2019 Aug 13;19(1):181. (PMID: 31409325)
Arch Ophthalmol. 2008 May;126(5):608-17. (PMID: 18474769)
Invest Ophthalmol Vis Sci. 2015 Feb 09;56(2):918-31. (PMID: 25667399)
Optom Vis Sci. 2013 May;90(5):488-93. (PMID: 23563443)
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4007-15. (PMID: 16249474)
Optom Vis Sci. 2009 Feb;86(2):139-45. (PMID: 19156007)
Qual Life Res. 2020 Mar;29(3):775-781. (PMID: 31673921)
JAMA Ophthalmol. 2016 Sep 1;134(9):959-66. (PMID: 27466983)
Am J Ophthalmol. 2007 Aug;144(2):238-244. (PMID: 17560843)
Invest Ophthalmol Vis Sci. 2013 Nov 13;54(12):7431-8. (PMID: 24150757)
J Clin Epidemiol. 2010 Nov;63(11):1179-94. (PMID: 20685078)
Transl Vis Sci Technol. 2018 Jul 18;7(4):6. (PMID: 30034950)
Invest Ophthalmol Vis Sci. 2011 Oct 11;52(11):8042-6. (PMID: 21896857)
Br J Ophthalmol. 2013 Feb;97(2):145-8. (PMID: 23212205)
Australas J Ageing. 2008 Dec;27(4):170-6. (PMID: 19032617)
Semin Ophthalmol. 2014 Jul;29(4):202-4. (PMID: 24702438)
Eye (Lond). 2017 May;31(5):741-748. (PMID: 28085147)
J Cataract Refract Surg. 2004 Feb;30(2):287-90. (PMID: 15030802)
J Affect Disord. 2010 Apr;122(1-2):86-95. (PMID: 19616305)
Clin Exp Ophthalmol. 2012 Dec;40(9):840-8. (PMID: 22394378)
Psychol Res Behav Manag. 2014 Apr 10;7:115-24. (PMID: 24748826)
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4732-41. (PMID: 17065481)
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7451-61. (PMID: 26595605)
Ophthalmic Physiol Opt. 2016 Sep;36(5):584-606. (PMID: 27580757)
BMC Psychiatry. 2020 May 12;20(1):224. (PMID: 32398122)
Res Dev Disabil. 2014 Jul;35(7):1734-41. (PMID: 24679546)
Multivariate Behav Res. 2015;50(6):569-83. (PMID: 26717119)
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137. (PMID: 28194657)
Ophthalmic Physiol Opt. 2019 Sep;39(5):378-391. (PMID: 31468574)
BMJ Open. 2017 Jan 12;7(1):e013261. (PMID: 28082366)
Gen Hosp Psychiatry. 2013 Sep-Oct;35(5):551-5. (PMID: 23664569)
Int J Mol Sci. 2019 Nov 14;20(22):. (PMID: 31739639)
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1291-1298. (PMID: 29730797)
Cochrane Database Syst Rev. 2017 Apr 28;4:CD002902. (PMID: 28452408)
JAMA Ophthalmol. 2013 May;131(5):573-81. (PMID: 23471505)
Med Care. 2007 May;45(5 Suppl 1):S22-31. (PMID: 17443115)
Semin Ophthalmol. 2017;32(4):428-437. (PMID: 27082703)
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):927-35. (PMID: 11923230)
Health Policy. 1990 Dec;16(3):199-208. (PMID: 10109801)
J Rehabil Res Dev. 2013;50(8):1157-68. (PMID: 24458902)
Health Qual Life Outcomes. 2006 Oct 11;4:79. (PMID: 17034633)
Am J Ophthalmol. 2021 Feb;222:60-68. (PMID: 32858027)
Optometry. 2010 Sep;81(9):461-8. (PMID: 20591747)
Am J Ophthalmol. 2017 May;177:169-174. (PMID: 28237413)
Arch Ophthalmol. 2008 Jul;126(7):975-80. (PMID: 18625946)
Optom Vis Sci. 2012 Sep;89(9):1399-408. (PMID: 22902419)
JAMA Ophthalmol. 2017 Feb 1;135(2):96-104. (PMID: 27978569)
J Rehabil Res Dev. 2011;48(9):1101-8. (PMID: 22234714)
Res Dev Disabil. 2013 Dec;34(12):4565-70. (PMID: 24176255)
Grant Information:: K12 EY022299 United States EY NEI NIH HHS; K23 EY026985 United States EY NEI NIH HHS; K23 EY027848 United States EY NEI NIH HHS; TL1 TR002242 United States TR NCATS NIH HHS
Entry Date(s):: Date Created: 20201214 Date Completed: 20210723 Latest Revision: 20220503
Update Code:: 20240104
PubMed Central ID:: PMC8184579
DOI:: 10.1016/j.ajo.2020.12.001
PMID:: 33309692
: Czasopismo naukowe

Full Text Finder

Objective: We sought to construct and validate a patient-reported outcome measure for screening and monitoring vision-related anxiety in patients with inherited retinal degenerations.
Design: Item-response theory and graded response modeling to quantitatively validate questionnaire items generated from qualitative interviews and patient feedback.
Methods: Patients at the Kellogg Eye Center (University of Michigan, Ann Arbor, Michigan, USA) with a clinical diagnosis of an inherited retinal degeneration (n = 128) participated in an interviewer-administered questionnaire. The questionnaire consisted of 166 items, 26 of which pertained to concepts of "worry" and "anxiety." The subset of vision-related anxiety questions was analyzed by a graded response model using the Cai Metropolis-Hastings Robbins-Monro algorithm in the R software mirt package. Item reduction was performed based on item fit, item information, and item discriminability. To assess test-retest variability, 25 participants completed the questionnaire a second time 4 to 16 days later.
Results: The final questionnaire consisted of 14 items divided into 2 unidimensional domains: rod function anxiety and cone function anxiety. The questionnaire exhibited convergent validity with the Patient Health Questionnaire for symptoms of depression and anxiety. This vision-related anxiety questionnaire has high marginal reliability (0.81 for rod-function anxiety, 0.83 for cone-function anxiety) and exhibits minimal test-retest variability (ρ = 0.81 [0.64-0.91] for rod-function anxiety and ρ = 0.83 [0.68-0.92] for cone-function anxiety).
Conclusions: The Michigan Vision-Related Anxiety Questionnaire is a psychometrically validated 14-item patient-reported outcome measure to be used as a psychosocial screening and monitoring tool for patients with inherited retinal degenerations. It can be used in therapeutic clinical trials for measuring the benefit of an investigational therapy on a patient's vision-related anxiety.
(Copyright © 2021 Elsevier Inc. All rights reserved.)

Informacja